Key result
Novel spiroisatin derivative 15j potently inhibits mPTP opening while preserving ATP production in vitro.
Why the study?
Myocardial ischemia-reperfusion injury remains a major clinical challenge driven by mitochondrial dysfunction and cell death, motivating the development of novel modulators of the mitochondrial permeability transition pore (mPTP) targeted at the c-ring of F1/FO-ATP synthase.
Spiroisatin derivatives, particularly compound 15j, show promise as preclinical cardioprotective agents against ischemia-reperfusion injury by inhibiting mPTP opening at nanomolar potency while preserving ATP production and promoting mitochondrial quality control.
Answers are grounded in this paper and cite their sources.
Should not change clinical practice for ischemia-reperfusion injury; leaves open mPTP modulation as a research target.
Ischemia−reperfusion injury remains a major clinical challenge due to mitochondrial dysfunction and cell death. Here we report a novel series of spiroisatin derivatives as modulators of the mitochondrial permeability transition pore (mPTP) targeted at the c-ring of F1/FO-ATP synthase. Structure−activity relationship analysis identified compound 15j with nanomolar in vitro potency in inhibiting mPTP opening while preserving ATP production. Molecular modeling supported distinct binding interactions within the c subunit of F1/FO-ATP synthase, rationalizing observed pharmacodynamics. Beyond mPTP inhibition, 15j positively modulates mitochondrial quality control pathways, including mitophagy and biogenesis, contributing to sustained mitochondrial homeostasis after reperfusion. These findings establish spiroisatin derivatives as a promising class of cardioprotective agents acting through convergent mechanisms on mitochondrial integrity and quality control.
No takes yet. Share an insight, caveat, or question.
Albanese et al. (2026) studied Myocardial ischemia-reperfusion injury. Spiroisatin derivatives (compound 15j) was evaluated on Inhibition of mitochondrial permeability transition pore (mPTP) opening. Spiroisatin derivative compound 15j demonstrated nanomolar in vitro potency in inhibiting mitochondrial permeability transition pore opening while preserving ATP production.
Synapse has enriched 10 related papers. Consider them for comparative context: